FIND ARTICLE

Volume: 
Issue: 
1
Date of issue: 

Neuroblastoma is the most common extracranial tumour of childhood. Despite of the applica- tion of intensive treatment regiments, the majority of high-risk patients are eventually relapsing. This stresses the need for new therapeutical approaches to eradicate residual tumour cells, which might impro- ve the survival of the high-risk group neuroblastoma patients. Immunotherapy of neuroblastoma is one of the currently developed strategies. In this publication recent data on application of immunotherapy in neuroblastoma treatment have been reviewed. They include the publications investigating neuroblastoma interactions with immune system. Clinically tested and preclinically developed approaches engaging the immune system to fight the tumour have been reviewed. They include data on development of the passive and active therapies targeting a neuroblastoma antigen GD2 ganglioside, as well as application of modified tumour cells and dendritic cells as vaccines.

Author of the article: 

The Editorial Board
Andrzej Łukaszyk - przewodniczący, Zofia Bielańska-Osuchowska, Szczepan Biliński, Mieczysław Chorąży, Aleksander Koj, Włodzimierz Korochoda, Leszek Kuźnicki, Aleksandra Stojałowska, Lech Wojtczak

Editorial address:
Katedra i Zakład Histologii i Embriologii Uniwersytetu Medycznego w Poznaniu, ul. Święcickiego 6, 60-781 Poznań, tel. +48 61 8546453, fax. +48 61 8546440, email: mnowicki@ump.edu.pl

PBK Postępby biologi komórki